NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab	Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor	Not yet recruiting	Phase 2	2026-08-21		NCT07261241

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Jubilant DraxImage Inc.	2
New Approaches to Neuroblastoma Therapy Consortium	7
United Therapeutics	18

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
C.S Mott Children's Hospital	Ann Arbor	United States	7
Children Hospital of Colorado	Aurora	United States	4
Children's Healthcare of Atlanta	Atlanta	United States	47
Children's Hospital and Regional Medical Center - Seattle	Seattle	United States	3
Children's Hospital Los Angeles	Los Angeles	United States	6
Children's Hospital of Philadelphia	Philadelphia	United States	6
Children's Memorial Hospital - Chicago	Chicago	United States	2
Childrens Hospital Boston, Dana-Farber Cancer Institute.	Boston	United States	4
Cincinnati Children's Hospital Medical Center	Cincinnati	United States	21
Cook Children's Medical Center - Fort Worth	Fort Worth	United States	2
St. Jude Children's Research Hospital	Memphis	United States	194
UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	United States	11
University of Texas Southwestern	Dalls	United States	1